大葉大學圖書館 |

Ketamine for treatment-resistant depression[electronic resource] :the first decade of progress /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.781
書名/作者:	Ketamine for treatment-resistant depression : the first decade of progress // edited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
其他作者:	Mathew, Sanjay J.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	xix, 155 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Ketamine - Therapeutic use.
標題:	Medicine.
標題:	Psychopharmacology.
標題:	Medicine & Public Health.
ISBN:	9783319429250
ISBN:	9783319429236
內容註:	1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.
摘要、提要註:	This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
電子資源:	http://dx.doi.org/10.1007/978-3-319-42925-0

Ketamine for treatment-resistant depression[electronic resource] :the first decade of progress /
Ketamine for treatment-resistant depressionthe first decade of progress /[electronic resource] :edited by Sanjay J. Mathew, Carlos A. Zarate, Jr. - Cham :Springer International Publishing :2016. - xix, 155 p. :ill., digital ;24 cm.

1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

ISBN: 9783319429250

Standard No.: 10.1007/978-3-319-42925-0doiSubjects--Topical Terms:

687730
Ketamine
--Therapeutic use.

LC Class. No.: RD86.K4

Dewey Class. No.: 615.781

Ketamine for treatment-resistant depression[electronic resource] :the first decade of progress /
LDR:03771nam a2200313 a 4500 001 476730
003 DE-He213
005 20161130075614.0
006 m d
007 cr nn 008maaau
008 181208s2016 gw s 0 eng d
020 $a 9783319429250 $q (electronic bk.)
020 $a 9783319429236 $q (paper)
024 7 $a 10.1007/978-3-319-42925-0 $2 doi
035 $a 978-3-319-42925-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RD86.K4
072 7 $a MMGW $2 bicssc
072 7 $a MED105020 $2 bisacsh
082 0 4 $a 615.781 $2 23
090 $a RD86.K4 $b K43 2016
245 0 0 $a Ketamine for treatment-resistant depression $h [electronic resource] : $b the first decade of progress / $c edited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2016.
300 $a xix, 155 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.
520 $a This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation "ketamine-like" fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
650 0 $a Ketamine $x Therapeutic use. $3 687730
650 0 $a Medicine. $3 373206
650 0 $a Psychopharmacology. $3 372108
650 1 4 $a Medicine & Public Health. $3 463493
700 1 $a Mathew, Sanjay J. $3 687728
700 1 $a Zarate, Carlos A. $3 687729
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-42925-0
950 $a Medicine (Springer-11650)